Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Atea Pharmaceuticals (AVIR) Return on Equity (2020 - 2026)

Atea Pharmaceuticals' Return on Equity history spans 7 years, with the latest figure at 0.01% for Q1 2026.

  • Quarterly Return on Equity changed 0.0% to 0.01% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.01% through Mar 2026, changed 0.0% year-over-year, with the annual reading at 0.0% for FY2025, 0.0% changed from the prior year.
  • Return on Equity came in at 0.01% for Q1 2026, down from 0.01% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2022 to a low of 0.01% in Q1 2026.
  • The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.0%.
  • The largest YoY upside for Return on Equity was 0bps in 2022 against a maximum downside of 0bps in 2022.
  • Atea Pharmaceuticals' Return on Equity stood at 0.0% in 2022, then tumbled by -35bps to 0.0% in 2023, then crashed by -57bps to 0.0% in 2024, then plummeted by -43bps to 0.01% in 2025, then dropped by -24bps to 0.01% in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Return on Equity are 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.0% (Q3 2025).